{
    "clinical_study": {
        "@rank": "132830", 
        "arm_group": {
            "arm_group_label": "Pediatric patients undergoing TPE", 
            "arm_group_type": "Other", 
            "description": "octaplas\u2122"
        }, 
        "brief_summary": {
            "textblock": "To assess the safety and tolerability of octaplas\u2122 in the pediatric population by monitoring\n      serious adverse drug reactions, adverse drug reactions (ADRs), thrombotic events (TEs),\n      thromboembolic events (TEEs) and by measuring safety laboratory parameters."
        }, 
        "brief_title": "Octaplas Pediatric Plasma Exchange Trial", 
        "completion_date": {
            "#text": "October 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Adverse Effects in the Therapeutic Use of Plasma Substitutes", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patients in whom therapeutic plasma exchange is required.\n\n          2. Patient is male or female \u22654 years to \u2264 20 years of age.\n\n          3. Patient must be a minimum of 15 kg and not require RBC priming for his/her plasma\n             exchange machine.\n\n          4. Patient or patient's legal representative(s)/guardian(s) have given     voluntarily\n             written and signed informed consent before any study-related procedure is to be\n             performed. If children are old enough (age usually deemed by each institution) to\n             understand the risks and benefits of the study, they should also be informed and\n             provide their written assent.\n\n        Exclusion Criteria:\n\n          1. Patient with known homozygous congenital deficiency of Protein S.\n\n          2. Patient has a history of severe hypersensitivity reaction to plasma-derived products\n             or to any excipient of the investigational product.\n\n          3. Patient has an already known IgA deficiency with documented antibodies against IgA.\n\n          4. Patient is currently participating in another interventional clinical study or has\n             participated during the past 1 month prior to study inclusion.\n\n          5. Patient is pregnant.\n\n          6. Patient is currently undergoing therapeutic plasma exchange (TPE) with regular plasma\n             (no exclusion for patients treated with albumin)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "20 Years", 
            "minimum_age": "4 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01938378", 
            "org_study_id": "LAS-213"
        }, 
        "intervention": {
            "arm_group_label": "Pediatric patients undergoing TPE", 
            "description": "octaplas\u2122 infusion solution for IV administration, ABO compatibile.  Recommended dose for a plasma exchange is 40 to 60 ml/kg.", 
            "intervention_name": "Octaplas\u2122", 
            "intervention_type": "Biological", 
            "other_name": "octaplas"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "April 21, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Atlanta", 
                    "country": "United States", 
                    "state": "Georgia", 
                    "zip": "30322"
                }, 
                "name": "Emory University"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-label, Multicenter, Post-Marketing Requirement Study to Investigate the Safety and Tolerability of Octaplas\u2122 in the Management of Pediatric Patients Who Require Therapeutic Plasma Exchange", 
        "overall_contact": {
            "email": "michael.eppolito@octapharma.com", 
            "last_name": "Michael Eppolito, MBA"
        }, 
        "overall_official": {
            "affiliation": "Medical Director", 
            "last_name": "Wolfgang Frenzel, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "April 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Primary Endpoint is the monitoring of adverse drug reactions, TEs and TEEs caused by the octaplas\u2122used for plasma exchange.", 
            "measure": "Primary objective is to assess safety and tolerability of octaplas\u2122 in the pediatric population by monitoring ADRs, TEs, TEEs, and by measuring safety laboratory parameters.", 
            "safety_issue": "Yes", 
            "time_frame": "up to 8 days including the 24 hour follow-up from treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01938378"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Assessment of safety laboratory parameters and investigator's assessment of overall safety.", 
            "safety_issue": "Yes", 
            "time_frame": "up to 8 days including the 24 hour follow-up"
        }, 
        "source": "Octapharma", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Octapharma", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}